silvestrol

Silvestrol is a natural product belonging to the rocaglate class, isolated from the fruits and twigs of Aglaia foveolata. It is a **cyclopenta[b]benzofuran flavagline** compound with a unique dioxanyloxy group, which is thought to contribute to its potent cytotoxic activity. Silvestrol acts as a selective inhibitor of the eukaryotic initiation factor 4A (eIF4A), blocking the initiation of protein translation in eukaryotic cells. This translational inhibition leads to decreased expression of pro-survival and pro-growth proteins such as Mcl-1 and cyclin D1. Silvestrol induces apoptosis mainly through the mitochondrial (apoptosome) pathway, involving caspase-2, caspase-9, and caspase-10 activation, along with disruption of the mitochondrial membrane potential and cytochrome c release. It shows potent cytotoxicity against a range of cancer cell lines, including chronic lymphocytic leukemia, mantle cell lymphoma, hepatocellular carcinoma, glioblastoma, prostate cancer, and others, with demonstrated activity in animal models. Its mechanism is considered distinct from current standard therapies, and development for cancer indications, especially B-cell malignancies and hepatocellular carcinoma, has reached preclinical and early clinical trial phases. However, silvestrol has unfavorable pharmacokinetic traits, including rapid conversion to inactive metabolites and apparent sensitivity to drug efflux mechanisms—factors that have complicated its pharmaceutical development[1][2][3][4][5][6].